127 related articles for article (PubMed ID: 24240582)
1. A systematic review of hypermethylation of p16 gene in esophageal cancer.
Xu R; Wang F; Wu L; Wang J; Lu C
Cancer Biomark; 2013; 13(4):215-26. PubMed ID: 24240582
[TBL] [Abstract][Full Text] [Related]
2. Meta-analysis demonstrates no association between p16
Jiang Y; Yan F; Liang L; Wan Y; Liu J; Cheng W
Arch Gynecol Obstet; 2017 Mar; 295(3):697-704. PubMed ID: 28000027
[TBL] [Abstract][Full Text] [Related]
3. CDKN2A methylation in esophageal cancer: a meta-analysis.
Zhou C; Li J; Li Q
Oncotarget; 2017 Jul; 8(30):50071-50083. PubMed ID: 28637022
[TBL] [Abstract][Full Text] [Related]
4. Meta-analysis of CDKN2A methylation to find its role in prostate cancer development and progression, and also to find the effect of CDKN2A expression on disease-free survival (PRISMA).
Cao Z; Wei L; Zhu W; Yao X
Medicine (Baltimore); 2018 Mar; 97(12):e0182. PubMed ID: 29561434
[TBL] [Abstract][Full Text] [Related]
5. p16 hypermethylation: a biomarker for increased esophageal cancer susceptibility in high incidence region of North East India.
Das M; Saikia BJ; Sharma SK; Sekhon GS; Mahanta J; Phukan RK
Tumour Biol; 2015 Mar; 36(3):1627-42. PubMed ID: 25361631
[TBL] [Abstract][Full Text] [Related]
6. Molecular detection of p16 promoter methylation in the serum of patients with esophageal squamous cell carcinoma.
Hibi K; Taguchi M; Nakayama H; Takase T; Kasai Y; Ito K; Akiyama S; Nakao A
Clin Cancer Res; 2001 Oct; 7(10):3135-8. PubMed ID: 11595706
[TBL] [Abstract][Full Text] [Related]
7. Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk.
Schulmann K; Sterian A; Berki A; Yin J; Sato F; Xu Y; Olaru A; Wang S; Mori Y; Deacu E; Hamilton J; Kan T; Krasna MJ; Beer DG; Pepe MS; Abraham JM; Feng Z; Schmiegel W; Greenwald BD; Meltzer SJ
Oncogene; 2005 Jun; 24(25):4138-48. PubMed ID: 15824739
[TBL] [Abstract][Full Text] [Related]
8. In situ analysis of p16/INK4 promoter hypermethylation in esophageal carcinoma and gastric carcinoma.
Zhang F; Wang L; Wu PP; Yan ZW; Zheng L; Yu YY; Jiang XC
Chin J Dig Dis; 2004; 5(4):149-55. PubMed ID: 15612883
[TBL] [Abstract][Full Text] [Related]
9. Aberrant promoter hypermethylation of p16 gene in endometrial carcinoma.
Hu ZY; Tang LD; Zhou Q; Xiao L; Cao Y
Tumour Biol; 2015 Mar; 36(3):1487-91. PubMed ID: 25596080
[TBL] [Abstract][Full Text] [Related]
10. p16 expression in Barrett's esophagus and esophageal adenocarcinoma: association with genetic and epigenetic alterations.
Hardie LJ; Darnton SJ; Wallis YL; Chauhan A; Hainaut P; Wild CP; Casson AG
Cancer Lett; 2005 Jan; 217(2):221-30. PubMed ID: 15617840
[TBL] [Abstract][Full Text] [Related]
11. Relationships between p16 gene promoter methylation and clinicopathologic features of colorectal cancer: a meta-analysis of 27 cohort studies.
Chen YZ; Liu D; Zhao YX; Wang HT; Gao Y; Chen Y
DNA Cell Biol; 2014 Oct; 33(10):729-38. PubMed ID: 24979649
[TBL] [Abstract][Full Text] [Related]
12. Promoter hypermethylation of p16 and APC in gastrointestinal cancer patients.
Erdem B; Küçükyıldırım S; Sağlar E; Polat Z; Mergen H
Turk J Gastroenterol; 2014 Oct; 25(5):512-7. PubMed ID: 25417611
[TBL] [Abstract][Full Text] [Related]
13. P16
Tuo L; Sha S; Huayu Z; Du K
Thorac Cancer; 2018 Aug; 9(8):1032-1040. PubMed ID: 29927090
[TBL] [Abstract][Full Text] [Related]
14. Promoter hypermethylation patterns of P16, DAPK and MGMT in oral squamous cell carcinoma: a systematic review and meta-analysis.
Don KR; Ramani P; Ramshankar V; Sherlin HJ; Premkumar P; Natesan A
Indian J Dent Res; 2014; 25(6):797-805. PubMed ID: 25728117
[TBL] [Abstract][Full Text] [Related]
15. Aberrant DNA methylation of P16, MGMT, and hMLH1 genes in combination with MTHFR C677T genetic polymorphism in esophageal squamous cell carcinoma.
Wang J; Sasco AJ; Fu C; Xue H; Guo G; Hua Z; Zhou Q; Jiang Q; Xu B
Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):118-25. PubMed ID: 18199718
[TBL] [Abstract][Full Text] [Related]
16. Aberrant p16 methylation, a possible epigenetic risk factor in familial esophageal squamous cell carcinoma.
Abbaszadegan MR; Raziee HR; Ghafarzadegan K; Shakeri MT; Afsharnezhad S; Ghavamnasiry MR
Int J Gastrointest Cancer; 2005; 36(1):47-54. PubMed ID: 16227635
[TBL] [Abstract][Full Text] [Related]
17. High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to aflatoxin B1-DNA adduct levels in human hepatocellular carcinoma.
Zhang YJ; Ahsan H; Chen Y; Lunn RM; Wang LY; Chen SY; Lee PH; Chen CJ; Santella RM
Mol Carcinog; 2002 Oct; 35(2):85-92. PubMed ID: 12325038
[TBL] [Abstract][Full Text] [Related]
18. A meta-analysis of serum p16 gene promoter methylation for diagnosis of nonsmall cell lung cancer.
Yan R; Chi L; Zheng X; Sun R; You J; Ye X
Indian J Cancer; 2015 Dec; 52 Suppl 2():e116-8. PubMed ID: 26728668
[TBL] [Abstract][Full Text] [Related]
19. Associations of risk factors obesity and occupational airborne exposures with CDKN2A/p16 aberrant DNA methylation in esophageal cancer patients.
Mohammad Ganji S; Miotto E; Callegari E; Sayehmiri K; Fereidooni F; Yazdanbod M; Rastgar-Jazii F; Negrini M
Dis Esophagus; 2010 Sep; 23(7):597-602. PubMed ID: 20459442
[TBL] [Abstract][Full Text] [Related]
20. The reduced expression and aberrant methylation of p16(INK4a) in chromate workers with lung cancer.
Kondo K; Takahashi Y; Hirose Y; Nagao T; Tsuyuguchi M; Hashimoto M; Ochiai A; Monden Y; Tangoku A
Lung Cancer; 2006 Sep; 53(3):295-302. PubMed ID: 16828922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
